Product category:
Clinical chemistry analysis
News Release from: Bio-Rad Life Science | Subject: BioPlex 2200
Edited by the Laboratorytalk Editorial
Team on 31 May 2006
FDA clearance for automated multiplexing
Novel automated multiplexing technology streamlines patient testing and maximizes laboratory efficiency
Bio-Rad Laboratories has received marketing clearance from the US Food and Drug Administration (FDA) for its new BioPlex 2200 system, a revolutionary new immunoassay platform that employs multiplexing technology to analyze for multiple disease states from single patient samples It is the first clinical diagnostics platform to offer multiplexing technology on a fully-automated, fully-integrated random access platform
This article was originally published on Laboratorytalk on 9 Dec 2004 at 8.00am (UK)
Related stories
Multiplex assay system has new software
Available in 21 CFR Part 11 and standard versions, both containing many features for additional flexibility, performance and ease of use
FDA approval for new HIV-1/HIV-2 rapid test
First FDA-approved single use test available in the USA to differentiate between HIV-1 and HIV-2 antibodies
The system was unveiled in July 2004 at the American Association of Clinical Chemistry meeting and will soon be available in the USA.
"We are excited about receiving FDA clearance for this important new technology and look forward to making it available to clinical laboratories".
"This unique system will improve the quality of patient testing, decrease turnaround time and eliminate the traditionally labor-intensive processes involved in specialty diagnostics".
"The development of the BioPlex 2200 system is another example of Bio-Rad's commitment to providing valuable tools that enable laboratories to improve testing methods, maximize efficiencies and lower costs," said John Goetz, vice president of Bio-Rad's clinical diagnostics group.
The BioPlex 2200 system is a fully automated bead-based multiplexing immunoassay platform that can deliver up to 2200 results per hour.
The system will initially include a panel of assays targeting autoimmune diagnostics.
Future assays in development are in the areas of serology, infectious disease, cardiac and toxicology.
• Bio-Rad Life Science: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
